MLSS vs SRDX vs XRAY vs NVCR

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -12. 2% for Milestone Scientific Inc. (MLSS). Analysts rate Surmodics, Inc. (SRDX) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Surmodics, Inc.

(SRDX) delivered a total return of -22. 1%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: SRDX returned +88. 4% versus MLSS's -80. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Surmodics, Inc.

(SRDX) is the lower-risk stock at 0. 52β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 316% more volatile than SRDX relative to the S&P 500. On balance sheet safety, Milestone Scientific Inc. (MLSS) carries a lower debt/equity ratio of 6% versus 184% for DENTSPLY SIRONA Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -12. 2% for Milestone Scientific Inc. (MLSS). On earnings-per-share growth, the picture is similar: Milestone Scientific Inc. grew EPS 37. 9% year-over-year, compared to -645. 5% for Surmodics, Inc.. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Surmodics, Inc.

(SRDX) is the more profitable company, earning -9. 2% net margin versus -54. 6% for Milestone Scientific Inc. — meaning it keeps -9. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XRAY leads at 6. 8% versus -78. 3% for MLSS. At the gross margin level — before operating expenses — MLSS leads at 74. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

In this comparison, XRAY (5.

9% yield) pays a dividend. MLSS, SRDX, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Surmodics, Inc.

(SRDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 52)). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SRDX: +88. 4%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MLSS is a small-cap quality compounder stock; SRDX is a small-cap quality compounder stock; XRAY is a small-cap income-oriented stock; NVCR is a small-cap quality compounder stock. XRAY pays a dividend while MLSS, SRDX, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.